Urolithin A: The Postbiotic Compound Getting Attention for Mitochondrial Health

Urolithin A is drawing interest in longevity and healthy-aging research because of its potential relationship to mitochondrial quality control. It is also a useful example of how emerging supplement ingredients can be biologically interesting without yet having definitive evidence for broad health outcomes.
For women over 40, the topic may be relevant as part of a wider conversation about maintaining strength and physical function with age. For supplement brand owners, it raises practical questions about clinical evidence, ingredient sourcing, serving size, and responsible claims. Understanding the science begins with the cell structures at the center of the research.
Mitochondria: The Cell’s Energy-Producing Structures
Mitochondria are small structures inside most cells. They help convert energy from food into adenosine triphosphate, or ATP, which cells use to carry out many functions. Because of this role, mitochondria are often described as the cell’s “powerhouses.”
That familiar phrase is useful, but incomplete. Mitochondria also participate in processes such as cellular signaling and the regulation of cell stress responses. Their number and condition can vary by tissue and change over time. In muscle, mitochondrial function is one area researchers study in relation to endurance and physical performance.

What Is Mitophagy?
Cells have systems for identifying and removing worn or damaged components. Mitophagy is the selective removal and recycling of mitochondria through cellular housekeeping pathways. In simplified terms, it is one part of the process by which cells manage mitochondrial quality.
Urolithin A has been studied for its relationship to mitophagy-related pathways. This does not mean that a supplement has been shown to “clean out” mitochondria or restore youthful cells. In human studies, researchers have examined biomarkers and functional measures that may relate to mitochondrial health; direct evidence of increased mitophagic activity in human muscle remains limited.

How Urolithin A Is Made in the Body
Urolithin A is not typically present in foods in meaningful amounts. Instead, it can be produced when gut bacteria metabolize ellagitannins and related compounds found in foods such as pomegranates, walnuts, and some berries. The ability to produce it varies among individuals because the required microbial conversion differs from person to person.
Studies often describe only a subset of participants, sometimes roughly one third, as natural urolithin producers, although the proportion varies with the population and methods studied. Other people may produce different urolithins or little to no urolithin A. Therefore, eating a food containing ellagitannins does not guarantee that a person will produce a particular amount of urolithin A.
This microbiome dependence helps explain the interest in direct supplementation: it bypasses the gut-bacteria conversion step. However, individual differences in response and the long-term effects of supplementation remain open research questions. Urolithin A is sometimes described as a postbiotic-like metabolite in consumer discussions, but that label should not be taken as evidence of a specific clinical benefit.
What Human Studies Have Found So Far
Human evidence is emerging, not conclusive. Trials have investigated urolithin A at doses generally around 500–1,000 mg per day, with study duration and outcomes varying.
A randomized clinical trial published in JAMA Network Open enrolled 66 adults aged 65–90 and compared 1,000 mg per day with placebo for four months. Researchers reported improvements in certain fatigue-limited muscle contraction measures after several weeks. Both groups improved on the six-minute walk test, but the between-group difference was not statistically significant. The results therefore do not establish that urolithin A improves overall walking capacity or prevents age-related muscle decline (Liu et al., 2022).
A separate randomized trial in middle-aged adults studied 500 mg and 1,000 mg per day for 120 days. It reported changes in selected muscle-strength, exercise-performance, and mitochondrial-health measures. These findings are promising, but they are outcome-specific and do not demonstrate a universal effect across all measures or populations (Singh et al., 2022).
Taken together, these trials provide an early human evidence base, but they do not show that urolithin A prevents disease, extends lifespan, reverses aging, or reliably improves physical performance for everyone. Biomarker changes and improvements in selected performance tests are not equivalent to disease prevention. Larger and longer studies, including research that directly evaluates mitophagy in human tissues, would help clarify the picture. A systematic review of human urolithin A research also reflects the still-developing nature of the evidence.
Safety and Practical Considerations
Urolithin A was generally well tolerated in the short-term human trials cited above. Those studies involved relatively small groups and follow-up periods ranging from weeks to a few months, however, so they cannot establish long-term safety or safety for every population.
Consultation with a qualified healthcare professional is advisable for people who are pregnant or breastfeeding, managing a health condition, or taking medication. This is particularly important when considering a new supplement alongside an existing care plan. The available trial evidence should not be interpreted as a substitute for individualized medical advice.
Formulation Considerations for Supplement Brands
For brands, the studied dose range has a direct impact on the product format. A daily serving of 500–1,000 mg can make capsules a multi-unit serving, while sachets or powders may offer more capacity. A 500 mg gummy serving can be challenging because of the space required for the active ingredient, along with texture, taste, and manufacturing constraints.
Several development checks are especially relevant:
- Confirm material identity and potency. Specifications should identify the particular urolithin A material and support the declared amount per serving.
- Assess stability. Stability testing should evaluate the ingredient in the complete formulation and selected packaging, rather than relying only on raw-material data.
- Match format to serving size. Capsule count, sachet size, and gummy feasibility should be considered early in product development.
- Use combinations selectively. Adding multiple “longevity” ingredients without a clear formulation rationale can complicate dose, stability, consumer understanding, and substantiation.
- Review claims before launch. Structure/function wording should be carefully substantiated. Disease-treatment, disease-prevention, “reverses aging,” and similar claims are not supported by the evidence summarized here. The Federal Trade Commission’s health-products compliance guidance explains the importance of competent and reliable scientific support for health-related advertising.
A methodical development process can help align the ingredient specification, study evidence, serving format, label, and consumer-facing claims. SolisLabs supports supplement brands with formulation and product development through packaging; further information is available through its R&D formulation process and company overview.
A Promising Research Area, Not a Proven Longevity Shortcut
Urolithin A offers a compelling research story: gut microbes can convert food-derived compounds into a metabolite that researchers are investigating for its relationship to mitochondrial quality control. Direct supplementation may bypass variation in that conversion, while questions about long-term effects, individual response, and meaningful health outcomes remain unresolved.
For consumers, the current evidence supports measured interest rather than sweeping expectations. For brands, careful sourcing, realistic serving-format decisions, and evidence-aligned claims are central to responsible product development.

